Open AccessUse of favipiravir against Covid-19: A Review
Author(s) -
Eiman Syed,
Mati Ullah,
Ataul Mustafa,
Sana Ashiq
Publication year - 2022
Publication title -
pakistan biomedical journal
Language(s) - English
Resource type - Journals
eISSN - 2709-2798
pISSN - 2709-278X
DOI - 10.54393/pbmj.v5i1.202
Subject(s) - favipiravir , medicine , covid-19 , medline , intensive care medicine , web of science , disease , meta analysis , infectious disease (medical specialty) , political science , law
Coronavirus disease 2019 (COVID-19) emerged as a global challenge for the world healthcare community. The use of favipiravir against COVID-19 was studied in various studies but its efficacy and side effects remain uncertain. Therefore, we aimed to analyze the use of favipiravir in patients suffering from coronavirus.The literature search was done by using several databases including MEDLINE, Google Scholar, Web of Science, PubMed, and Science Direct. To ensure the credibility and accuracy of the included articles we include only those studies that were published in indexed journals. Furthermore, in this current review, we mainly include only those studies published from January 2015 to September2021. We included all the review and research articles published in the English language.The review of currently available literature suggests the use of favipiravir showed both some utility and side effects in patients diagnosed with coronavirus-19. Moreover, the use of this antiviral drug may show a promising role in mild to moderate COVID-19 patients and it may reduce the need for prolonged hospital stay and mechanical ventilation. But there is still a need to confirm the side effects and favipiravir efficacy in the patients suffering from this fatal disease.